TG Therapeutics, Inc. or Ultragenyx Pharmaceutical Inc.: Who Invests More in Innovation?

Ultragenyx leads in R&D investment over TG Therapeutics.

__timestampTG Therapeutics, Inc.Ultragenyx Pharmaceutical Inc.
Wednesday, January 1, 20143135478145967000
Thursday, January 1, 201543445817114737000
Friday, January 1, 201666489820183204000
Sunday, January 1, 201796886134231644000
Monday, January 1, 2018153793000293998000
Tuesday, January 1, 2019148369000357355000
Wednesday, January 1, 2020151934000412084000
Friday, January 1, 2021198532000497153000
Saturday, January 1, 2022112128000705789000
Sunday, January 1, 202376192000648449000
Loading chart...

Unlocking the unknown

Investing in Innovation: TG Therapeutics vs. Ultragenyx Pharmaceutical

In the competitive world of biotechnology, innovation is key. Over the past decade, TG Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc. have been at the forefront, investing heavily in research and development (R&D) to drive breakthroughs. From 2014 to 2023, Ultragenyx consistently outpaced TG Therapeutics, with R&D expenses peaking at approximately 705 million in 2022, a staggering 500% increase from 2014. In contrast, TG Therapeutics saw a more modest growth, with R&D spending increasing by about 140% over the same period. This trend highlights Ultragenyx's aggressive strategy in pioneering new treatments, while TG Therapeutics maintains a steady, albeit slower, pace. As the biotech landscape evolves, these investments underscore the companies' commitment to innovation, potentially shaping the future of healthcare. The data reveals a clear narrative: Ultragenyx is leading the charge in R&D, setting a high bar for its competitors.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025